Lyophilisation Conference 2019

SMi Group3 - 4 June 2019, London, UK
SMi Group announces the return of the 7th Annual Lyophilisation Conference. Lyophilisation (or freeze drying) remains one of the most exciting and rapidly advancing technologies in the pharmaceutical industry to date. By 2020, the lyophilisation equipment market is projected to exceed 8% CAGR reaching approximately £4.4 billion.

Attend this conference along with key opinion leaders from all areas of pharmaceuticals and biologicals to explore formulation science, materials characterisation, novel and alternative technologies, mathematical modelling and regulatory updates.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2019

  • Sune Klint Andersen, Principal Spray Drying,Janssen Pharmaceuticals
  • Xiaodong Chen, Senior Research Investigator,Bristol-Myers Squibb

Key Speakers include

  • Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC
  • Davide Fissore, Associate Professor, Politecnico di Torino
  • Michael Dekner, Head Fill & Finish LCM support, Takeda
  • Richard Denk, Head Sales Containment, Skan AG
  • Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D
  • Daryl Williams, Professor of Particle Science and Director of Discovery space, Imperial College London
  • Kevin Ward, Director of R&D, Biopharma technology
  • Paul Barry, Development Scientist, Genzyme Ireland Ltd/Sanofi

2019 Highlights

  • Explore the recent advances in lyophilisation methods and technologies from Biopharma Technology
  • Discuss the novel methods that characterise complex pharmaceutical products to aid formulation design from NIBSC
  • Gain insight into the approaches to avoid cross contamination during lyophilisation from SKAN AG
  • Discover a new approach towards process design through the use of micro freeze dryers by Politecno di Torino
  • Examine the use of model-based approach to lyophilisation cycle design from Takeda

For further information and to register, please visit:
http://www.lyophilisation-europe.com/wpnwe

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Bayer inks deals with eleven startups under G4A Di…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup c...

Akcea and Pfizer Inc. announce licensing agreement…

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the com...